Risk and clinical course of retinopathy of prematurity in 78 infants of gestational age 22-25 weeks.
Citation: Journal of Aapos: American Association for Pediatric Ophthalmology & Strabismus. 18(3):266-70, 2014 Jun.PMID: 24924282Institution: MedStar Washington Hospital CenterDepartment: OphthalmologyForm of publication: Journal ArticleMedline article type(s): Comparative Study | Journal Article | Research Support, N.I.H., Extramural | Research Support, Non-U.S. Gov'tSubject headings: *Gestational Age | *Retinopathy of Prematurity/di [Diagnosis] | Birth Weight | Humans | Infant | Infant, Very Low Birth Weight | Intensive Care Units, Neonatal | Laser Coagulation | Proportional Hazards Models | Retinopathy of Prematurity/mo [Mortality] | Retinopathy of Prematurity/su [Surgery] | Retrospective Studies | Risk Factors | Survival Rate | Time FactorsISSN:- 1091-8531
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | Available | 24924282 |
CONCLUSIONS: The 2013 screening guidelines appear to be appropriate for infants of 22 and 23 weeks' GA when ROP screening begins at PMA 31 weeks.Copyright � 2014 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.
METHODS: This study was a comparative case series for the total set of 78 infants <25 GA screened for ROP at a level IV NICU during a 21-month period. Data are presented on infants screened for ROP from 6 weeks after birth for 22 and 23 weeks' GA infants and from 5 weeks after birth for 24 and 25 weeks' GA. Accounting for the competing risk of mortality, we implemented Cox CR regression models to assess birth weight, GA, and admission diagnosis as potential risk factors for the following time to event outcomes: type 1 disease, aggressive posterior ROP (AP-ROP), plus disease, first presentation of ROP, and worst ROP observed.
PURPOSE: To characterize the retinopathy of prematurity (ROP) and survival of infants born at gestational age (GA) of 22-25 weeks.
RESULTS: Risk of laser treatment (subhazard ratio [SHR] = 0.56, P = 0.007) and of plus disease (SHR = 0.49, P = 0.001) was increased among those born at lower GA. Twenty infants required laser for type 1 disease at median postmenstrual age (PMA) of 35.8 weeks (range, 33.0-42.7); infants with AP-ROP had laser at PMA of 34.5 weeks (range, 33.0-36.9), 2 weeks earlier than infants without AP-ROP at PMA 36.5 weeks (range, 33.9-42.7). The cumulative probability of receiving laser therapy approached 46% (22 or 23 weeks' GA), 30% (24 weeks' GA), and 18% (25 weeks' GA).
English